基本信息
views: 14
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
David Chien is SVP, Clinical Development at Krystal Biotech, Inc. David brings over a decade of experience across all phases of drug development. Prior to joining Krystal, David was the Executive Medical Director at Nektar, leading the global development of bempegaldesleukin, an immune-oncology program with multiple registrational trials in solid tumor indications. Prior to Nektar, David worked with Amgen, leading global development of oncology and rare disease biosimilars, including Riabni through submission for FDA approval. At AbbVie, David led early clinical development of lymphoma indications for Venclexta. David holds a Doctor of Medicine from the University of California, Davis. David completed his medical training in Internal Medicine internship at New York Hospital Queens, Nuclear Medicine residency and PET/CT fellowship at The John Hopkins Hospital.
Research Interests
Papers共 64 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
A.O. Siefker-Radtke,U. Hoch,Y. Loriot,A.V. Balar,M.A. Bilen,N.M. Tannir, D.C. Cho,A. Choudhury,D. Chien,D. Yu, S.L. Currie,J. Novotny,
Targeted Oncologyno. 5 (2020): 599-611
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn